title: [Clinical observation and long-time follow-up of patients with malignant lymphoma treated with autologous peripheral blood hematopoietic stem cell transplantation].
abstract: This study was purposed to evaluate the efficacy of autologous peripheral blood hematopoietic stem cell transplantation (auto-PBHSCT) for patients with malignant lymphoma. From January 1992 to June 2012, 32 malignant lymphoma (ML) patients were treated with auto-PBHSCT in our hospital. There were 56 cases of non-Hodgkins lymphoma (NHL) and 16 cases of Hodgkin's lymphoma(HD). The preconditioning regimens of total body irradiation (TBI) plus cyclophosphamide combined with etoposide/pharmorubicin were used in 50 patients, and the BEAM (BCNU+etoposide+Ara-C+melphalan) were used in the other 22 patients. The average number of CD34(+) cells was (6.6 ± 4.9) ×10(6)/kg. The results showed that transplanted cells were engrafted and hematopoiesis was reconstituted in all patients. The median time of neutrophilic granulocyte recovery up to ≥ 0.5×10(9)/L was 12 ± 4.4 days, and the platelet recovery up to ≥ 20×10(9)/L was 14 ± 4.9 days . The transplantation related mortality was 4.2%. The patients were followed up for 6-217 months. The median follow-up time was 63.5 months. 1-year OS rate was 92.3 ± 3.2%. 3-years OS rate was 81.4 ± 4.9%. 5-years OS rate was 77.6 ± 5.3%. 10-years OS rate was 68.9 ± 6.8%. It is concluded that auto-PBHSCT is effective for malignant lymphoma, and long time follow-up shows that the OS rate is still high. Furthermore, the safety of auto-PBHSCT can also be received. Before transplantation the patients with CR can get higher OS rate.
authors.affiliation: Department of Hematology, The 3rd Hospital, Peking University Beijing, 100191, China.
authors.forename: Kai
authors.initials: K
authors.lastname: Hu
authors.affiliation: Department of Hematology, The 3rd Hospital, Peking University Beijing, 100191, China.
authors.forename: Ji-Jun
authors.initials: JJ
authors.lastname: Wang
authors.affiliation: Department of Hematology, The 3rd Hospital, Peking University Beijing, 100191, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhao
authors.affiliation: Department of Hematology, The 3rd Hospital, Peking University Beijing, 100191, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Tian
authors.affiliation: Department of Hematology, The 3rd Hospital, Peking University Beijing, 100191, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Wan
authors.affiliation: Department of Hematology, The 3rd Hospital, Peking University Beijing, 100191, China. E-mail: xykbysy@163.com.
authors.forename: Xiao-Yan
authors.initials: XY
authors.lastname: Ke
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008223:Lymphoma / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D012189:Retrospective Studies; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D055815:Young Adult